Recipharm AB

Recipharm AB is one of the world’s largest Contract Development and Manufacturing Organizations (CDMOs), providing comprehensive pharmaceutical development, manufacturing, and lifecycle management services to pharmaceutical and biotechnology companies worldwide. Founded in 1995 and headquartered in Stockholm, Sweden, the company has expanded through strategic acquisitions into a global network of manufacturing and development facilities across Europe, North America, and Asia.

Recipharm offers end-to-end services covering formulation development, analytical testing, process optimization, sterile manufacturing, oral solid dosage production, inhalation products, biologics support, clinical trial material manufacturing, and commercial-scale production. The company supports customers throughout the entire pharmaceutical lifecycle—from early development and clinical trials to product launch and global commercialization.

With manufacturing sites approved by major international regulatory agencies, including the US FDA, EMA, MHRA, and other health authorities, Recipharm maintains a strong reputation for quality, reliability, and regulatory excellence. The company continuously invests in digital manufacturing, sustainability initiatives, automation, and advanced pharmaceutical technologies to meet the evolving needs of global healthcare organizations. Through scientific expertise, flexible manufacturing solutions, and long-term customer partnerships, Recipharm has established itself as one of Europe’s leading CDMO providers.